Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
Moderate Confidence RCTPrimary source: [Open]
Linked compounds: ss-31
Outcomes summary
Randomized clinical trial evaluating elamipretide (SS-31) in primary mitochondrial myopathy, reporting efficacy and safety outcomes for the studied endpoints in this population.
Limitations
Endpoint selection and heterogeneity of mitochondrial myopathy may limit generalizability; interpret results in context of trial design and follow-up duration.
Notes
Primary source: PMID 37268435.